At the pathogenesis level, CRC results from traditional pathways (KRAS/BRAF wild type), alternative pathways (KRAS mutation), and the serrated pathways (BRAF mutation - dMMR), representing 33.4%, 11.6%, and 0.8% of CRC cases in the Middle East, respectively [17]. The gene discussed is KRAS; the disease is colorectal carcinoma.